PRESENTATION
Q2 2020 — Results presentation
Q2 2020PDF · 26 pages3.1 MB
1 -- 1 of 26 -- 2nd Quarter 2020 Earnings Call July 16, 2020 -- 2 of 26 -- Cautionary Note on Forward-looking Statements 3 This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to our business, or on our ability to execute business continuity plans, as a result of the COVID-19 pandemic; economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in the company’s most recently filed Quarterly Report on Form 10-Q and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Cautionary Note on Non-GAAP Financial Measures This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company’s website at www.investor.jnj.com. -- 3 of 26 -- Strategic Partnerships, Collaborations & Licensing Arrangements 4 During the course of this morning’s presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. The following is an acknowledgement of those relationships: Immunology REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation, and TREMFYA discovered using MorphoSys AG antibody technology Neuroscience INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA includes technology licensed from Alkermes Pharma Ireland Limited, RISPERDAL CONSTA developed in collaboration with Alkermes, Inc Infectious Diseases PREZCOBIX/ REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA developed in collaboration with ViiV Healthcare UK Cardiovascular/ Metabolism/Other INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation, XARELTO co-developed with Bayer HealthCare AG, PROCRIT/ EPREX licensed from Amgen Inc., and X-Linked Retinitis Pigmentosa: AAV-RPGR licensed from MeiraGTx Oncology IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company, ZYTIGA licensed from BTG International Ltd., VELCADE developed in collaboration with Millennium: The Takeda Oncology Company, DARZALEX licensed from Genmab A/S, BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc., and cusatuzumab licensed and developing in collaboration argenx BVBA and argenx SE, ERLEADA is licensed from Regents of California and Memorial Sloan Kettering, BCMA CAR-T licensed and developed in collaboration with Legend Biotech USA Inc., Legend Biotech Ireland Limited (“Legend”), subsidiaries of GenScript Biotech Corporation, niraparib licensed from TESARO, Inc., an oncology-focused business within GSK, and DuoBody platform licensed from Genmab relates to several bispecific antibody programs; ENHANZE platform licensed from Halozyme Therapeutics, Inc. Pulmonary Hypertension UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan Global Public Health Janssen’s Monovalent Ebola Vaccine is developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S. The program has benefited from funding and preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, NIAID support included 2 product development contracts starting in 2008 and 8 pre-clinical services contracts. This program is also receiving funding from the IMI2 Joint Undertaking under EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). The IMI2 Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Further funding for the Ebola vaccine regimen has been provided by the BARDA, within the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, under Contract Numbers HHSO100201700013C and HHSO100201500008C.. The initial work on Ebola was conducted which was extended from 2002 until 2011. 2002 and 2007 via a Cooperative Research and Development Agreement (CRADA is AI-0114) between Janssen/Crucell and the Vaccine Research Center (VRC)/NIAID, part of the NIH. Janssen/Crucell have licenses to much of VRC’s Ebola IP specific for human adenovirus under the Ad26/Ad35 Ebola vaccine CRADA invention. VAC69120 (Filovirus multivalent vaccine) developed in collaboration with Bavarian Nordic; funding: NIH Division of Microbiology and Infectious Diseases (DMID), under Contract Number HHSN272200800056C -- 4 of 26 -- Sales Performance and Earnings Review COVID-19 Vaccine Update Capital Allocation and Guidance Q&A 5 Agenda 1 2 3 4 Joseph J. Wolk Executive Vice President, Chief Financial Officer Chris DelOrefice Vice President, Investor Relations Alex Gorsky Chairman and Chief Executive Officer Paul Stoffels, M.D. Vice Chairman of the Executive Committee & Chief Scientific Officer Joaquin Duato Vice Chairman of the Executive Committee -- 5 of 26 -- Regional Sales Results Q2 2020 Q2 2019 % CHANGE Reported Operational1 U.S. $9.5 $10.4 (8.3)% (8.3)% Europe 4.1 4.7 (14.2) (11.5) Western Hemisphere (ex U.S.) 1.1 1.5 (22.1) (8.9) Asia-Pacific, Africa 3.6 4.0 (9.3) (7.7) International 8.8 10.2 (13.4) (9.6) Worldwide (WW) $18.3 $20.6 (10.8)% (9.0)% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Note: Values may not add due to rounding 2nd Quarter 2020 Sales Dollars in Billions 6 -- 6 of 26 -- (35.3)%; (34.5)%1 Q2 2020 Q2 2019 $1.67 $2.58 2nd Quarter 2020 Financial Highlights Dollars in Billions, except EPS Reported %; Operational %1 7 Sales Adjusted Earnings2 Adjusted EPS2 (10.8)%; (9.0)%1 $18.3 $20.6 GAAP Earnings (35.3)% $3.6 $5.6 (36.0)% Q2 2020 Q2 2019 GAAP EPS (34.6)% $1.36 $2.08 Q2 2020 Q2 2020 Q2 2019 Q2 2019 Q2 2020 Q2 2019 $4.4 $7.0 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website -- 7 of 26 -- OTC $1,149 Skin Health/Beauty $1,007 Oral Care $397 Baby Care $356 Women's Health $202 Wound Care/Other $185 $3,296 (7.0%), (3.6%) WW Sales $MM ■ Reported Growth ■ Operational Growth1 Consumer Health Highlights – 2nd Quarter 2020 OTC and Oral Care strength offset by COVID-19 impact 8 Key Drivers of Operational Performance1 OTC • Increase primarily due to market and share growth driven by COVID-19 demand primarily in Pain. PEPCID growth due to competitive withdrawal as well as ZARBEE’s NATURAL’s strength in the U.S. partially offset by COVID-19 consumption declines in China in Pain and Cough & Cold Skin Health/ Beauty • Decline primarily driven by COVID-19 impacts in the U.S. and APAC. NEUTROGENA market and consumption declines primarily across Sun Care, Facial Care, and Makeup in the U.S. Oral Care • Increase primarily due to market and share growth for LISTERINE mouthwash due to increased demand related to COVID-19 primarily in the U.S.; promotional activity and new product launched in APAC Baby Care • Decline due to Baby Center divestiture, SKU rationalization and COVID-19 related impacts in APAC along with prior year relaunch activities in EMEA partially offset by strength in AVEENO baby Women’s Health • Decline due to COVID-19 impacts driven by lockdowns and destocking Wound Care/Other • Decline due to COVID-19 impacts in adhesive bandages in Japan and reduced market demand in tapes and wraps in the U.S. Adjusted Operational Sales2: WW (3.4)%, U.S. 2.0%, Int’l (7.5)% Reported: WW (7.0)%, U.S. 1.3%, Int’l (13.4)% Operational1: WW (3.6)%, U.S. 1.3%, Int’l (7.4)% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding 7.9%, 10.7% (20.1)%, (11.8)% (4.0)%, (2.1)% (19.7)%, (13.6)% 2.2%, 6.3% (16.2)%, (14.3)% -- 8 of 26 -- Key Drivers of Operational Performance1 Immunology • Growth driven by strong uptake of STELARA in Crohn’s Disease and Ulcerative Colitis, strength in TREMFYA in Psoriasis, and U.S. market growth, partially offset by COVID-19 • REMICADE decline due to increased discounts/rebates and biosimilar competition Infectious Diseases • Driven by strong sales of SYMTUZA in the U.S. and launch uptake of JULUCA in the EU, partially offset by increased competition for PREZISTA/PREZCOBIX/REZOLSTA and PREZISTA OUS LOE Neuroscience • Paliperidone long-acting injectables growth due to strength of INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA from new patient starts and persistency, partially offset by cannibalization of RISPERDAL CONSTA, and the negative impact of COVID-19 Oncology • DARZALEX continued strong market growth and share gains in the U.S., partially offset by the negative impact of COVID-19 and a one-time pricing adjustment in the EU in 2019 • Strong sales of IMBRUVICA due to increased patient uptake globally, higher market share primarily in CLL L1, partially offset by COVID-19 • Continued strong global launch uptake of ERLEADA and share gains in non-metastatic CRPC as well as recently approved mCSPC indication • Lower sales and share of VELCADE and ZYTIGA due to generic competition Cardiovascular/ Metabolism/ Other (CVM/Other) • Decline driven by lower sales of PROCRIT/EPREX due to biosimilar competition • Modest growth in XARELTO due to TRx growth and a one-time prior period pricing adjustment, partially offset by increased rebates • INVOKANA/INVOKAMET growth due to EU and LATAM uptake and a one-time prior period pricing adjustment in the U.S., partially offset by U.S. share declines due to competitive pressures and higher rebates Pulmonary Hypertension (PH) • Growth in OPSUMIT and UPTRAVI due to continued share gains, market growth, and improved payer mix • Lower sales of TRACLEER due to generic competition and cannibalization from OPSUMIT Adjusted Operational Sales2: WW 3.9%, U.S. 5.8%, Int’l 1.5% Immunology $3,523 Infectious Diseases $878 Neuroscience $1,587 Oncology $2,791 CVM/Other $1,184 PH $789 $10,752 2.1%, 3.9% WW Sales $MM ■ Reported Growth ■ Operational Growth1 Pharmaceutical Highlights – 2nd Quarter 2020 Growth across most therapeutic areas despite COVID-19 impacts 9 Reported: WW 2.1%, U.S. 5.8%, Int’l (2.4)% Operational1: WW 3.9%, U.S. 5.8%, Int’l 1.4% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding (7.1)%, (5.8)% 14.2%, 15.0% 3.5%, 5.7% 3.2%, 5.2% 1.9%, 4.7% 1.6%, 3.0% -- 9 of 26 -- Orthopaedics $1,451 Surgery $1,551 Vision $695 Interventional Solutions $590 $4,288 (33.9)%, (32.7)% WW Sales $MM ■ Reported Growth ■ Operational Growth1 Medical Devices Highlights – 2nd Quarter 2020 Sales decline driven by the negative impact of COVID-19 10 Reported: WW (33.9)%, U.S. (39.6)%, Int’l (28.8)% Operational1: WW (32.7)%, U.S. (39.6)%, Int’l (26.4)% Key Drivers of Operational Performance1 Interventional Solutions • Driven by the negative impact of COVID-19 partially offset by double-digit growth in China Orthopaedics • Hips: Driven by the negative impact of COVID-19; continued leadership position in the anterior approach • Knees: Driven by the negative impact of COVID-19 • Trauma: Driven by reductions in general activity, travel and recreation due to COVID-19 • Spine, Sports & Other: Driven by the negative impact of COVID-19 partially offset by strong uptake of SYMPHONY in Spine • Spine: WW: ~(36%), U.S.: ~(43%), OUS: ~(27%) Surgery • Advanced: • Endocutters: ~(27%) Primarily driven by the negative impact of COVID-19 coupled with competitive pressures in the U.S. • Biosurgery: ~(13%) Driven by the negative impact of COVID-19 partially offset by growth of SURGIFLO after prior year supply disruption • Energy: ~(27%) Primarily driven by the negative impact of COVID-19 coupled with competitive pressures in the U.S. • General: Driven by the negative impact of COVID-19 and an unfavorable prior period pricing adjustment in the U.S. Vision • Contact Lenses/Other: Negatively impacted by COVID-19 resulting in less new wearers entering the category and lower consumption of existing wearers • Surgical: Primarily driven by the negative impact of COVID-19 coupled with competitive pressures in the U.S. Adjusted Operational Sales2: WW (32.5)%, U.S. (39.5)%, Int’l (26.1)% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding (21.5)%, (20.5)% (40.1)%, (39.3)% (34.7)%, (33.9)% (34.1)%, (32.2)% -- 10 of 26 -- Condensed Consolidated Statement of Earnings 1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 11 2020 2019 % Increase (Decrease) Amount % to Sales Amount % to Sales Sales to customers $18,336 100.0 $20,562 100.0 (10.8) Cost of products sold 6,579 35.9 6,940 33.8 (5.2) Gross Profit 11,757 64.1 13,622 66.2 (13.7) Selling, marketing, and administrative expenses 4,993 27.2 5,546 27.0 (10.0) Research and development expense 2,707 14.8 2,666 13.0 1.5 In-process research and development 6 0.0 - - Interest (income) expense, net 26 0.2 (5) 0.0 Other (income) expense, net 24 0.1 (1,683) (8.2) Restructuring 61 0.3 57 0.2 Earnings before provision for taxes on income 3,940 21.5 7,041 34.2 (44.0) Provision for taxes on income 314 1.7 1,434 6.9 (78.1) Net Earnings $3,626 19.8 $5,607 27.3 (35.3) - Net earnings per share (Diluted) $1.36 $2.08 (34.6) Average shares outstanding (Diluted) 2,665.5 2,691.7 Effective tax rate 8.0% 20.4% . Adjusted earnings before provision for taxes and net earnings1 Earnings before provision for taxes on income $5,337 29.1 $8,614 41.9 (38.0) Net earnings $4,446 24.2 $6,950 33.8 (36.0) Net earnings per share (Diluted) $1.67 $2.58 (35.3) Effective tax rate 16.7% 19.3% 2nd Quarter 2020 (Unaudited; Dollar and Shares in Millions Except Per Share Figures) -- 11 of 26 -- Adjusted Income Before Tax by Segment1 2nd Quarter 2020 12 Pharmaceutical Medical Devices3 Consumer Health Expenses Not Allocated to Segments 2Q 2020 2Q 2019 Pharmaceutical 44.1% 41.6% Medical Devices 1.2% 57.5% Consumer Health 24.0% 20.9% Total 29.1% 41.9% 1 Non-GAAP measure; excludes amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 2 Estimated as of 7/16/2020 3 2019 includes approximately $2.0 billion related to the divestiture of the Advanced Sterilization Products (ASP) business. Note: Values may not add due to rounding % to Sales -- 12 of 26 -- COVID-19 Vaccine R&D and Manufacturing Update -- 13 of 26 -- -- 14 of 26 -- Capital Allocation Strategy Capital Allocation Organic growth business needs Free cash flow1 Priorities are clear and remain unchanged Competitive dividends Share repurchases HIGHER PRIORITY LOWER PRIORITY Investment in M&A Dollars in Billions Q2 2020 Cash and Marketable Securities $19.1 Debt ($30.4) Net Debt ($11.3) Free Cash Flow2 ~$5.5 Q2 2020: $2.7B invested in R&D $2.7B in dividends paid to shareholders Note: values may have been rounded 1 Non-GAAP measure; cash flow from operations less CAPEX 2 Estimated as of July 16, 2020 15 -- 15 of 26 -- Healthcare Industry Macroeconomic Perspective 16 Encouraging trends for many procedures approaching pre- COVID-19 levels Patients Office Visits Improving office visits compared to earlier stages of the pandemic Public educational materials and resources to increase patient confidence and inspire people to prioritize their health Consumers U.S. category growth trends improved from height of lockdowns The impact of the pandemic is very fluid and likely to continue evolving -- 16 of 26 -- • Expectations remain unchanged • Recent improvement in number of patient interactions with Health Care Providers • Continued above market growth 17 2020 Guidance Pharmaceutical • Expectations remain unchanged • Impact to certain categories as a result of reduced store traffic, government lockdowns, and social distancing behaviors • SKU rationalization program proceeding as planned • Above market growth in the U.S. Consumer Health Informed Assumptions • Utilized external expert assessments related to the macroeconomic impact of COVID-19 • Discussions with hospital systems, administrators, and surgeons on preparedness and treatment paradigm • Extensive analytics on weekly hospital trends by account -- 17 of 26 -- Medical Devices: Q2 Monthly Trends 18 Variance vs. Original Expectations to Start the Year (January Guidance) Franchise June Q2 Contact Lenses (30%) (40%) Surgical Vision (45%) (55%) Biosurgery / Endocutters / Energy (20%) (30%) Wound Closure (20%) (30%) Hips (10%) (40%) Knees (25%) (55%) Spine (15%) (35%) Trauma (10%) (20%) Electrophysiology (10%) (30%) Total Medical Devices (25%) (35%) -50% -40% -30% -20% -10% 0% January February March April May June Variance vs. Original Expectations Medical Devices 2 Note: Values are rounded -- 18 of 26 -- Countries Impacted: China, Japan, Korea • China represented more than 40% of total MD impact in Q1 • Japan and Korea represented less than 5% of total MD impact in Q1 • China declined (5%) vs. original expectations in January, but grew +11%1 vs. 2019 • Japan and Korea declined (25%) vs. original expectations in January Current estimate: • Decline of (10%) to (25%) April assumptions: • Decline of (15%) to (35%) Current estimate: • Impact of (15%) to 0% April assumptions: • Impact of 0% to +10% ~20% of MD Sales Major Markets: US, Italy, France, Germany, UK, Russia, Spain • U.S. represented ~30% of total MD impact in Q1 • Remaining major markets represented less than 20% of total MD impact in Q1 • U.S. declined (40%) vs. original expectations in January with June declining (20%) • Germany declined (25%) vs. original expectations in January with June declining (15%) • Remaining markets declined (45%) vs. original expectations ~60% of MD Sales Rest of World • ROW represented more than 5% of total MD impact in Q1 • ROW declined (45%) vs. original expectations ~20% of MD Sales Medical Devices: COVID-19 Framework 19 Full Year 2020 Operational Sales Impact inclusive of Q2 YTD Actuals: ($3.75B) to ($5.25B) Initial Impact Significant Impact Stabilization Recovery Overall economy, unemployment, insurance coverage and procedure capacity are key variables that could impact rate of recovery Total Worldwide Medical Devices Total Worldwide Medical Devices Q1 Q2 Q4 Q3 1 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website 1 Note: Values are rounded -- 19 of 26 -- 0 20 40 60 80 100 120 January February March April May June July August September October November December 20 Medical Devices: Procedural Guidance Update April Guidance Actuals Original Expectations % 2020 Original Expectations Attainment Full Year 2020 Operational Sales Impact inclusive of Q2 YTD Actuals: ($3.75B) to ($5.25B) July Guidance -- 20 of 26 -- 2020 Guidance 1 Non-GAAP measure; excludes acquisitions and divestitures 4 Non-GAAP measure; excludes intangible amortization expense and special items 2 Non-GAAP measure; excludes the impact of translational currency 5 Sales less: COGS, SM&A and R&D expenses 3 Euro Average Rate: July 2020 = $1.12 21 July April Comments Adjusted Operational Sales1,2 (0.8%) - 1.0% (3.0%) - 0.5% Improved Medical Devices outlook Operational Sales2 $81.0 - $82.5B (1.3%) - 0.5% $79.2 - $82.2B (3.5%) - 0.0% Net Impact Acq./Div: ~0.5% Estimated Reported Sales 3 $79.9B - $81.4B (2.6%) - (0.8%) $77.5B - $80.5B (5.5%) - (2.0%) FX ($1.1B) or (1.3%) impact Adjusted Pre-Tax Operating Margin4,5 ~100 bps decline ~100 bps decline Net Interest Expense / (Income) $50 - $150 million $50 - $150 million Net Other Income4 $0.8 - $1.0 billion $0.8 - $1.0 billion Effective Tax Rate4 16.5% - 17.5% 16.5% - 18.0% Tightening of range Adjusted EPS (Operational)2,4 $7.85 - $8.05 (9.6%) - (7.3%) $7.65 - $8.05 (11.9%) - (7.3%) Midpoint of $7.95 or (8.4%) Adjusted EPS (Reported)3,4 $7.75 - $7.95 (10.7%) - (8.4%) $7.50 - $7.90 (13.6%) – (9.0%) Midpoint of $7.85 or (9.6%) FX ($0.10) or (1.2%) impact -- 21 of 26 -- Pharmaceuticals 22 2021 Considerations Enterprise Medical Devices ‒ Plan to continue above market growth ‒ No anticipation of new biosimilar or generic competitors ‒ Assume procedures to be largely permissible throughout the year leading to double-digit operational sales growth ‒ Expect strong EPS growth on an operational basis ‒ OI&E projected to be consistent with 2020 ‒ 2020 additional 2 to 3 shipping days (53rd week) ‒ Focus on delivering solid growth in stronghold categories ‒ Projecting expansion of e-Commerce channel ‒ Full year SKU rationalization program profitability benefit expected Consumer Health -- 22 of 26 -- Medical Devices • Other: – Biosense Webster unveils late-breaking results from PRECEPT study in patients with persistent atrial fibrillation Pharmaceuticals • Regulatory Approvals: – IMBRUVICA (ibrutinib) – U.S. Food and Drug Administration (FDA) approval for the combination with rituximab for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who are new to therapy – DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) – FDA approval of a new subcutaneous formulation of daratumumab for the treatment of patients with multiple myeloma – SIRTURO (bedaquiline) – FDA approval of a new pediatric formulation as part of combination therapy to treat children with pulmonary multidrug-resistant tuberculosis – DARZALEX (daratumumab) – European Commission (EC) granted marketing authorization for subcutaneous formulation for all currently approved intravenous formulation indications – ZABDENO (Ad26.ZEBOV) and MYABEA (MVA-BN-Filo) – EC granted marketing authorization for the Janssen Ebola vaccine regimen for the prevention of Ebola Virus Disease1 – TREMFYA (guselkumab) – FDA approval for the treatment of adult patients with active psoriatic arthritis1 • Regulatory Submissions: – SIMPONI ARIA (golimumab) – Submission of two supplemental Biologics License Applications to the FDA for the treatment of polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis, in patients two years of age and older in combination with methotrexate • Other: – STELARA (ustekinumab) – Announced discontinuation of Phase 3 LOTUS study in Systemic Lupus Erythematosus – The Company announced acceleration of its COVID-19 vaccine candidate; Phase 1/2a clinical trial to begin in second half of July Notable New Announcements in 2nd Quarter 20201 23 1 These developments and all other news releases are available online in the Investors section of the company’s website at news releases -- 23 of 26 -- 24 -- 24 of 26 -- Q&A Paul Stoffels, M.D. Vice Chairman of the Executive Committee & Chief Scientific Officer Chairman and Chief Executive Officer Alex Gorsky Joseph J. Wolk Executive Vice President, Chief Financial Officer Joaquin Duato Vice Chairman of the Executive Committee -- 25 of 26 -- -- 26 of 26 --